Leukaemia Trial, Recruiting (NCT06229860)

Leukaemia Trial, Recruiting NCT06229860 Sponsor: University of California, Irvine Condition: Leukaemia

Printed from Voxsanity (voxsanity.com.au) — NCT06229860 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Leukaemia

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 18 years of age or older
People who have been diagnosed with chronic myeloid leukemia (CML) in a stage called the chronic phase (CML-CP)
People who are currently being treated with one of these four cancer medications: imatinib, dasatinib, bosutinib, or nilotinib
People who are a patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or who are a member of a patient support group run by the CML Buster Foundation
People who do not meet any of the exclusion criteria listed below

Who may not be able to join:

People who are unable to read and speak English
People who do not have the ability to make their own informed decision about taking part in the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 15 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mahtab Jafari, Pharm.D, Chao Family Comprehensive Cancer Center

Phone: 1-877-827-8839

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06229860

Sponsor: University of California, Irvine

Phase: Not Applicable

Status: Recruiting

Condition: Leukaemia

Trial contact: 1-877-827-8839

More information: https://clinicaltrials.gov/study/NCT06229860

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 18 years of age or older
People who have been diagnosed with chronic myeloid leukemia (CML) in a stage called the chronic phase (CML-CP)
People who are currently being treated with one of these four cancer medications: imatinib, dasatinib, bosutinib, or nilotinib
People who are a patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or who are a member of a patient support group run by the CML Buster Foundation
People who do not meet any of the exclusion criteria listed below

Who may not be able to join:

People who are unable to read and speak English
People who do not have the ability to make their own informed decision about taking part in the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 15 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of California, Irvine

Registry

ClinicalTrials.gov

Start date

25 January 2024

Est. completion

19 March 2025

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Assessment of adherence to TKI medication; Personality assessment; Assessment of quality of Life; Assessment of quality of Life and symptom burden

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov